United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 4 minute read Pharma Industry News MiNK Therapeutics surges over 700% after testicular cancer remission data fuels iNKT therapy optimism MiNK Therapeutics stock explodes 730% after iNKT cell therapy shows full remission in metastatic cancer. Read what’s driving investor frenzy. byPallavi MadhirajuJuly 12, 2025